.Pharmacolibrary.Drugs.ATC.P.P01BE03

Information

Artesunate is a semi-synthetic derivative of artemisinin, used for the treatment of severe and uncomplicated malaria. It acts rapidly against Plasmodium species and is recommended by WHO as first-line therapy for severe malaria. Artesunate is not approved in the US or EU for oral use but is used intravenously in many countries.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with severe malaria treated with intravenous artesunate.

References

1. Zaloumis, SG, et al., & Simpson, JA (2014). Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. CPT: pharmacometrics & systems pharmacology 3(11) e145–None. DOI:10.1038/psp.2014.43 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25372510

2. Cen, YY, et al., & Zhou, H (2018). [Research progress on pharmacokinetics and pharmacological activities of artesunate]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 43(19) 3970–3978. DOI:10.19540/j.cnki.cjcmm.20180726.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30453725

3. Haghiri, A, et al., & Simpson, JA (2023). Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria. Clinical pharmacology and therapeutics 114(6) 1304–1312. DOI:10.1002/cpt.3041 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37666798

Revisions

• 06/2025 initial generated model